Literature DB >> 26315404

Modulation of the Coagulation Cascade Using Aptamers.

Rebecca S Woodruff1, Bruce A Sullenger2.   

Abstract

As a novel class of therapeutics, aptamers, or nucleic acid ligands, have garnered clinical interest because of the ease of isolating a highly specific aptamer against a wide range of targets, their chemical flexibility and synthesis, and their inherent ability to have their function reversed. The following review details the development and molecular mechanisms of aptamers targeting specific proteases in the coagulation cascade. The ability of these anticoagulant aptamers to bind to and inhibit exosite function rather than binding within the active site highlights the importance of exosites in blocking protein function. As both exosite inhibitors and reversible agents, the use of aptamers is a promising strategy for future therapeutics.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  anticoagulation; aptamer; coagulation cascade; nucleic acids; serine endopeptidases

Mesh:

Substances:

Year:  2015        PMID: 26315404      PMCID: PMC5304947          DOI: 10.1161/ATVBAHA.115.300131

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  70 in total

1.  Where are all the aptamers?

Authors:  Geoffrey S Baird
Journal:  Am J Clin Pathol       Date:  2010-10       Impact factor: 2.493

2.  An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor.

Authors:  Jens Müller; Berend Isermann; Christina Dücker; Mohammad Salehi; Moritz Meyer; Max Friedrich; Thati Madhusudhan; Johannes Oldenburg; Günter Mayer; Bernd Pötzsch
Journal:  Chem Biol       Date:  2009-04-24

3.  Crystal structure of an RNA aptamer bound to thrombin.

Authors:  Stephen B Long; Meredith B Long; Rebekah R White; Bruce A Sullenger
Journal:  RNA       Date:  2008-10-29       Impact factor: 4.942

4.  Factor XII regulates the pathological process of thrombus formation on ruptured plaques.

Authors:  Marijke J E Kuijpers; Paola E J van der Meijden; Marion A H Feijge; Nadine J A Mattheij; Frauke May; José Govers-Riemslag; Joost C M Meijers; Johan W M Heemskerk; Thomas Renné; Judith M E M Cosemans
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-05-22       Impact factor: 8.311

5.  Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction.

Authors:  Bruce Sullenger; Rebecca Woodruff; Dougald M Monroe
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

Review 6.  Therapeutic RNA aptamers in clinical trials.

Authors:  Padma Sundaram; Helena Kurniawan; Mark E Byrne; Jacek Wower
Journal:  Eur J Pharm Sci       Date:  2012-11-07       Impact factor: 4.384

7.  First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.

Authors:  Christopher K Dyke; Steven R Steinhubl; Neal S Kleiman; Richard O Cannon; Laura G Aberle; Min Lin; Shelley K Myles; Chiara Melloni; Robert A Harrington; John H Alexander; Richard C Becker; Christopher P Rusconi
Journal:  Circulation       Date:  2006-11-13       Impact factor: 29.690

8.  Pharmacokinetics and biodistribution of novel aptamer compositions.

Authors:  Judith M Healy; Scott D Lewis; Markus Kurz; Ryan M Boomer; Kristin M Thompson; Charles Wilson; Thomas G McCauley
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

9.  Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers.

Authors:  S Oney; S M Nimjee; J Layzer; N Que-Gewirth; D Ginsburg; R C Becker; G Arepally; B A Sullenger
Journal:  Oligonucleotides       Date:  2007

10.  Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer.

Authors:  R S Woodruff; Y Xu; J Layzer; W Wu; M L Ogletree; B A Sullenger
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

View more
  14 in total

Review 1.  The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Authors:  Allison P Wheeler; David Gailani
Journal:  Hematol Oncol Clin North Am       Date:  2016-10       Impact factor: 3.722

Review 2.  Aptamers in HIV research diagnosis and therapy.

Authors:  Jyoti Bala; Srinivasan Chinnapaiyan; Rajib Kumar Dutta; Hoshang Unwalla
Journal:  RNA Biol       Date:  2018-02-12       Impact factor: 4.652

Review 3.  Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).

Authors:  Rami A Al-Horani
Journal:  Expert Opin Ther Pat       Date:  2019-12-19       Impact factor: 6.674

4.  Generation and characterization of aptamers targeting factor XIa.

Authors:  R S Woodruff; I Ivanov; I M Verhamme; M-F Sun; D Gailani; B A Sullenger
Journal:  Thromb Res       Date:  2017-06-09       Impact factor: 3.944

5.  Several structural motifs cooperate in determining the highly effective anti-thrombin activity of NU172 aptamer.

Authors:  Romualdo Troisi; Valeria Napolitano; Vera Spiridonova; Irene Russo Krauss; Filomena Sica
Journal:  Nucleic Acids Res       Date:  2018-12-14       Impact factor: 16.971

6.  The Evaluation of Pharmacodynamics and Pharmacokinetics of Anti-thrombin DNA Aptamer RA-36.

Authors:  Elena Zavyalova; Nadezhda Samoylenkova; Alexander Revishchin; Askar Turashev; Ilya Gordeychuk; Andrey Golovin; Alexey Kopylov; Galina Pavlova
Journal:  Front Pharmacol       Date:  2017-12-14       Impact factor: 5.810

Review 7.  Evolution of Complex Target SELEX to Identify Aptamers against Mammalian Cell-Surface Antigens.

Authors:  Prabodhika Mallikaratchy
Journal:  Molecules       Date:  2017-01-30       Impact factor: 4.411

Review 8.  Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers.

Authors:  Marie-Cécile Mercier; Monique Dontenwill; Laurence Choulier
Journal:  Cancers (Basel)       Date:  2017-06-21       Impact factor: 6.639

9.  Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer.

Authors:  Nancy J Ganson; Thomas J Povsic; Bruce A Sullenger; John H Alexander; Steven L Zelenkofske; Jeffrey M Sailstad; Christopher P Rusconi; Michael S Hershfield
Journal:  J Allergy Clin Immunol       Date:  2015-12-11       Impact factor: 10.793

10.  Thermodynamic, Anticoagulant, and Antiproliferative Properties of Thrombin Binding Aptamer Containing Novel UNA Derivative.

Authors:  Weronika Kotkowiak; Jolanta Lisowiec-Wachnicka; Jakub Grynda; Ryszard Kierzek; Jesper Wengel; Anna Pasternak
Journal:  Mol Ther Nucleic Acids       Date:  2017-12-30       Impact factor: 8.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.